Ruxolitinib found efficacious in patient with severe lupus miliaris disseminatus faciei: JAMA case report
Source- Gorham NC, Jacobs J, Wu SZ. Response of Severe Lupus Miliaris Disseminatus Faciei to Treatment With Ruxolitinib Cream. JAMA Dermatol. 2023 Apr 26. doi: 10.1001/jamadermatol.2023.0528. Epub ahead of print. PMID: 37099285.
Researchers have reported a case in JAMA in which Ruxolitinib was found efficacious in a patient with severe lupus miliaris disseminatus faciei.
Lupus miliaris disseminatus faciei (LMDF) is an non-infective granulomatous skin disease characterized by asymptomatic monomorphic smooth papules on the central face. It classically involves the lower eyelid, in conjunction with perifollicular granulomas on histology and can cause scarring. So early treatment isa key to reduce scarring. Tetracycline, isotretinoin, oral corticosteroids and dapsone have been found to be variably effective. Recently an article showing efficacy of ruxolitinib, a selective Janus kinase (JAK)–1/2 inhibitor in LMDF was published in JAMA Dermatology.
A 46-year-old otherwise healthy woman presented with numerous monomorphic, mildly erythematous, and skin-colored 1-mm to 2-mm smooth indurated papules on the face since 2-years which was gradually progressing. The papules coalesced into plaques that involved the upper and lower eyelids, forehead,medial cheeks, cutaneous lips, and chin. Punch biopsy from the lesion showed perifollicular noncaseating granulomas with multinucleated giant cells without a substantial lymphoid infiltrate. Acid-fast stain results for mycobacteria and periodic acid-
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.